1. Home
  2. XPL vs IMUX Comparison

XPL vs IMUX Comparison

Compare XPL & IMUX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Solitario Resources Corp.

XPL

Solitario Resources Corp.

N/A

Current Price

$0.75

Market Cap

64.6M

ML Signal

N/A

Logo Immunic Inc.

IMUX

Immunic Inc.

N/A

Current Price

$0.87

Market Cap

75.2M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
XPL
IMUX
Founded
1984
2016
Country
United States
United States
Employees
N/A
66
Industry
Precious Metals
Biotechnology: Pharmaceutical Preparations
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
64.6M
75.2M
IPO Year
2000
2013

Fundamental Metrics

Financial Performance
Metric
XPL
IMUX
Price
$0.75
$0.87
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
5
Target Price
$1.20
$5.00
AVG Volume (30 Days)
478.3K
3.8M
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
52.61
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.54
$0.51
52 Week High
$0.90
$1.35

Technical Indicators

Market Signals
Indicator
XPL
IMUX
Relative Strength Index (RSI) 53.28 59.14
Support Level $0.69 $0.61
Resistance Level $0.81 $0.92
Average True Range (ATR) 0.03 0.11
MACD -0.00 0.01
Stochastic Oscillator 56.12 46.07

Price Performance

Historical Comparison
XPL
IMUX

About XPL Solitario Resources Corp.

Solitario Resources Corp is exploration company engaging in acquiring, exploring, and developing zinc properties and other precious metals in safe jurisdictions in North and South America. It has joint venture interests in large, high-grade zinc development projects. The Florida Canyon Zinc Project in Peru is a development asset held jointly with Nexa Resources S.A., Golden Crest Project in South Dakota and the Lik Zinc Project represents a large-tonnage, high-grade development project in Alaska in partnership with Teck Resources. In addition, the company has an additional portfolio of exploration properties and royalties in the Americas.

About IMUX Immunic Inc.

Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function.

Share on Social Networks: